Helicobacter Pylori Clinical Trial
Official title:
A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole
Verified date | June 2018 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.
Status | Completed |
Enrollment | 30 |
Est. completion date | May 11, 2017 |
Est. primary completion date | April 17, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. HP positive participants. 2. Has body mass index between greater than (>) 18 and less than equal to (<=) 30 kilogram per square meter (kg/m^2) and weighs greater than equal to (>=) 50 kilogram (kg). 3. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1) until the Follow-up call on Day 17. Exclusion Criteria: 1. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1). 2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular consumption of 21 units or more units per week) at any time prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study (up to Day 17). 3. Has history of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison syndrome. 4. Has undergone therapeutic upper gastrointestinal endoscopic therapy (example, endoscopic hemostasis or excision including biopsy) within 30 days prior to Screening. 5. Has undergone major surgical procedures within the past 1 month or are scheduled to undergo surgical procedures that may affect gastric acid secretion (example, abdominal surgery, vagotomy, or craniotomy). 6. Has a history of cancer, except basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has been in remission for at least 5 years prior to Day 1. 7. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen at Screening. 8. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to Check-in. Cotinine test is positive at Screening or Check-in. 9. Has poor peripheral venous access. Has donated or lost 450 milliliter (mL) or more of his blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day 1. 10. Has abnormal Screening or Check-in laboratory values that suggest a clinically significant underlying disease or subject with the following laboratory abnormalities: alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin > the upper limit of normal (ULN). 11. Has reduced renal function assessed by having an estimated glomerular filtration rate <90 milliliter per min per 1.73 square meter (mL/min/1.73 m^2) (as estimated by Chronic Kidney Disease-Epidemology Collaboration) at Screening or Check-in. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Takeda |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) | Baseline up to Day 17 | ||
Primary | Percentage of Participants Who Discontinue Due to an Adverse Event (AE) | Baseline up to Day 17 | ||
Primary | Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose | Baseline up Day 15 | ||
Primary | Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose | Baseline up to Day 15 | ||
Primary | Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose | Baseline up to Day 15 | ||
Primary | Cmax: Maximum Observed Plasma Concentration for Bismuth | Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose | ||
Primary | AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth | Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose | ||
Primary | Aet: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth | Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05073367 -
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
|
||
Completed |
NCT00596401 -
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
|
||
Not yet recruiting |
NCT04101708 -
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT04029493 -
The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
|
||
Recruiting |
NCT04030715 -
The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study
|
N/A | |
Recruiting |
NCT04029415 -
The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
|
||
Not yet recruiting |
NCT02934048 -
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
|
Phase 4 | |
Not yet recruiting |
NCT02933229 -
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
|
Phase 4 | |
Recruiting |
NCT05184491 -
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
|
Phase 4 | |
Recruiting |
NCT05790525 -
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
|
Phase 4 | |
Completed |
NCT05790512 -
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
|
||
Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
Recruiting |
NCT05053945 -
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
|
||
Recruiting |
NCT05449028 -
Helicobacter Pylori Eradication Therapy in Portugal
|
N/A | |
Recruiting |
NCT00306280 -
Feasibility Study of Phototherapy System to Treat H Pylori
|
N/A | |
Active, not recruiting |
NCT02675010 -
Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study
|
N/A | |
Withdrawn |
NCT00467155 -
Helicobacter in The Gambia (Part 2)
|
N/A | |
Completed |
NCT03716622 -
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
|
Phase 4 | |
Not yet recruiting |
NCT04937426 -
Development of a Laboratory Test for the Detection of a Fluorescent-labeled Urease Inhibitor Marker Attached to Helicobacter Pylori
|
N/A |